Urodynamix Technologies is a Canadian medical device company that develops and commercializes non-invasive medical devices based on proprietary applications of near-infrared spectroscopy (NIRS) for the diagnosis of urological diseases and conditions, including:

• Urinary incontinence (UI)
• Lower urinary tract symptoms (LUTS)
• Prostate cancer and benign prostatic hyperplasia (BPH)
• Erectile dysfunction (ED)
• Intra-abdominal hypertension and abdominal compartment syndrome (ACS)

Urodynamix is led by President & CEO Barry Allen, who leads a highly experienced, industry proven management and development team.

Urodynamix is a publicly traded company and is listed on the TSX Venture Exchange under the symbol URO. 

The Company is certified to ISO 13485:2003 Medical Device Quality Management Systems standards.

The Technology

NIRS is an optical technique that has found widespread use in patient monitoring and non-invasive medical diagnostics.

Urodynamix’s initial NIRS technology was exclusively licensed from the University of British Columbia (UBC) in Vancouver, British Columbia. The Company has conducted extensive clinical studies and demonstrated the safety and efficacy of this non-invasive diagnostic technique for a range of diverse applications in the fields of urology, men’s health and patient monitoring.

Urodynamix’s technology complements existing diagnostic urology procedures and could quickly become a standard of care by replacing unnecessary invasive, catheter-based procedures. Urodynamix’s first product, the Tetra™Bladder Monitor System for non-invasive urodynamics, will be marketed by Laborie Medical Technologies, the world leader in diagnostic urology equipment beginning in 2008.